We are live on
!
Find out more
PAIA
Park Avenue Institutional Advisers Portfolio holdings
AUM
$199M
1-Year Est. Return
36.92%
This Fund
S&P 500
This Quarter
Est. Return
+0.18%
1 Year Est. Return
+36.92%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$199M
AUM Growth
-$514K
(-0.26%)
Cap. Flow
-$882K
Cap. Flow
% of AUM
-0.44%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
–
Closed
3
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$497K |
| 2 |
Braze
BRZE
|
+$210K |
| 3 |
TTAN
ServiceTitan Inc
TTAN
|
+$175K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 0% |
| 2 | Technology | 0% |
No holdings matched the selected filter criteria.
Similar funds
NI
PS
PMIA
PFA
KL
FTIA
SPI
BMA
Park Avenue Institutional Advisers's Q2 2026 Portfolio in Review
As of Q2 2026, Park Avenue Institutional Advisers held 5 positions worth $199M, down 0.26% from $199M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Park Avenue Institutional Advisers's Q2 2026 filing shows 3 closed positions. The largest sale was Revolution Medicines, an estimated $497K.
By sector, the portfolio is most concentrated in Healthcare at 0% of assets, down from 0.25% a quarter earlier, followed by Technology.
- Park Avenue Institutional Advisers fully exited Revolution Medicines in Q2 2026, selling an estimated $497K.
- Park Avenue Institutional Advisers's ten largest holdings make up 100% of its $199M portfolio in Q2 2026.
- Park Avenue Institutional Advisers opened 0 new positions and closed 3 in Q2 2026.
- Park Avenue Institutional Advisers's portfolio value fell 0.26% quarter-over-quarter to $199M.
Based on Park Avenue Institutional Advisers's 13F filing for Q2 2026, filed 4 Aug 2026.